Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 10/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.54 |
| ▸ | ATR | Q13535 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270892 | 0.83 | MTOR (0.63) | MTORKMT2APIK3CAATRCYP2C9 | |
| SCHEMBL1271807 | 0.82 | MTOR (0.65) | MTORPIK3CAATRCYP2C9PRKDC | |
| SCHEMBL2487544 | 0.78 | PIK3CA (0.43) | MTORPIK3CAATRCYP2C9PRKDC | |
| SCHEMBL1271420 | 0.77 | MTOR (1.00) | MTORKMT2APIK3CAATRCYP2C9 | |
| SCHEMBL3170376 | 0.76 | KMT2A (0.68) | MTORKMT2APIK3CAPOLBALDH1A1 | |
| SCHEMBL3943827 | 0.76 | KMT2A (0.56) | MTORKMT2ACYP2C9ALDH1A1KDM4E | |
| SCHEMBL1271439 | 0.76 | MTOR (0.81) | MTORKMT2APIK3CAATRCYP2C9 | |
| SCHEMBL1271359 | 0.76 | MTOR (0.81) | MTORKMT2APIK3CAATRCYP2C9 | |
| SCHEMBL2492087 | 0.75 | ATR (0.64) | MTORKMT2APIK3CAATR | |
| SCHEMBL4533051 | 0.75 | MTOR (0.64) | MTORKMT2APIK3CAATRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20100261723-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261723-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261723-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| EP-2057129-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009007749-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| EP-1979325-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008023180-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | TYMP, TYMS, PIK3CA | MTOR 4/4885KMT2A 2550/4885PIK3CA 3/4885 |
| US-20100261723-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MTOR, PIK3CA, TYMP | MTOR 1/4885KMT2A 2590/4885PIK3CA 2/4885 |
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | MTOR 3/4885KMT2A 2735/4885PIK3CA 20/4885 |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | MTOR 954/4885KMT2A 3348/4885PIK3CA 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.